163 related articles for article (PubMed ID: 16226096)
1. Clinical utility of the Food and Drug Administration Electrocardiogram Warehouse: a paradigm for the critical pathway initiative.
Cabell CH; Noto TC; Krucoff MW
J Electrocardiol; 2005 Oct; 38(4 Suppl):175-9. PubMed ID: 16226096
[TBL] [Abstract][Full Text] [Related]
2. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
3. What's next after 50 years of psychiatric drug development: an FDA perspective.
Laughren TP
J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
[TBL] [Abstract][Full Text] [Related]
4. Paving the critical path: how can clinical pharmacology help achieve the vision?
Lesko LJ
Clin Pharmacol Ther; 2007 Feb; 81(2):170-7. PubMed ID: 17259944
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
6. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
[TBL] [Abstract][Full Text] [Related]
7. Drug development and the FDA's Critical Path Initiative.
Woosley RL; Cossman J
Clin Pharmacol Ther; 2007 Jan; 81(1):129-33. PubMed ID: 17186012
[TBL] [Abstract][Full Text] [Related]
8. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
Woosley RL; Myers RT; Goodsaid F
Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
[TBL] [Abstract][Full Text] [Related]
9. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
[TBL] [Abstract][Full Text] [Related]
10. FDA reform in Congress: interview with Peter Barton Hutt. Food and Drug Administration. Interview by John S. James.
Hutt PB
AIDS Treat News; 1996 Apr; (no 245):4-5. PubMed ID: 11363623
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
13. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
Watson KT; Barash PG
Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
[TBL] [Abstract][Full Text] [Related]
14. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration.
Ball R; Horne D; Izurieta H; Sutherland A; Walderhaug M; Hsu H
Pediatrics; 2011 May; 127 Suppl 1():S31-8. PubMed ID: 21502249
[TBL] [Abstract][Full Text] [Related]
15. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
Reeve LM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
[TBL] [Abstract][Full Text] [Related]
16. Should biochemical markers of bone turnover be considered standard practice for safety pharmacology?
Henriksen K; Bohren KM; Bay-Jensen AC; Karsdal MA
Biomarkers; 2010 May; 15(3):195-204. PubMed ID: 19951005
[TBL] [Abstract][Full Text] [Related]
17. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.
Karsdal MA; Henriksen K; Leeming DJ; Mitchell P; Duffin K; Barascuk N; Klickstein L; Aggarwal P; Nemirovskiy O; Byrjalsen I; Qvist P; Bay-Jensen AC; Dam EB; Madsen SH; Christiansen C
Biomarkers; 2009 May; 14(3):181-202. PubMed ID: 19399662
[TBL] [Abstract][Full Text] [Related]
18. The critical path initiative: leveraging collaborations to enhance regulatory science.
Barratt RA; Bowens SL; McCune SK; Johannessen JN; Buckman SY
Clin Pharmacol Ther; 2012 Mar; 91(3):380-3. PubMed ID: 22343813
[TBL] [Abstract][Full Text] [Related]
19. Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II.
Giacoia GP; Mattison DR
Clin Ther; 2006 Sep; 28(9):1337-41. PubMed ID: 17062307
[TBL] [Abstract][Full Text] [Related]
20. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
Kesselheim AS; Mello MM
Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
